OCA represents the first-in-class of the FXR ligands approved for the treatment of ursodeoxycholic acid (UDCA)-resistant patients with primary biliary cholangitis (PBC), and has progressed in Phase III trials on NASH patients (FLINT study, and REGENERATE) [22]. This evidence concerns the gene NR1H4 and primary biliary cholangitis.